| Business Summary | | Diacrin,
Inc.
is
developing
cell
transplantation
technology
for
treating
human
diseases
that
are
characterized
by
cell
dysfunction
or
cell
death,
and
for
which
current
therapies
are
either
inadequate
or
nonexistent.
The
Company's
products
under
development
include
the
NeuroCell-PD
for
Parkinson's
disease;
porcine
neural
cells
for
stroke,
focal
epilepsy
and
chronic
intractable
pain;
porcine
spinal
cord
cells
for
spinal
cord
injury;
NeuroCell-HD
for
Huntington's
disease;
human
liver
cells
for
cirrhosis;
porcine
liver
cells
for
acute
liver
failure;
human
muscle
cells
for
cardiac
disease;
and
porcine
retinal
pigment
epithelial
cells
(porcine
RPE
cells)
for
muscular
degeneration. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | DCRN
is
developing
proprietary
populations
of
trans-plantable
porcine
cells
for
the
treatment
of
human
diseases
which
are
characterized
by
cell
dysfunction
or
cell
death
and
for
which
current
therapies
are
either
inadequate
or
nonexistent.
For
the
three
months
ended
3/31/01,
revenues
rose
50%
to
$1.3
million.
Net
loss
fell
35%
to
$811
thousand.
Revenues
reflect
an
increase
in
interest
income.
Net
loss
was
partially
offset
by
increased
research
and
development
expenses. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
990;
after
tax
earnings
were
-1,334. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Thomas Fraser, Ph.D., 53 Pres,
CEO | $295K | E. Michael Egan, 47 COO | 220K | Kevin Kerrigan, 29 Controller | -- | Albert Edge, P.h.D., 47 senior
director of molecular and cellular biology | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|